Alcon adds to surgical portfolio

Alcon has added a range of mydriatic, cycloplegic, diagnostic and anesthetic ophthalmic surgical products, according to a press release.

These products, transferred from Alcon’s parent company, Novartis, include:

Isopto atropine (atropine sulfate ophthalmic solution 1%) for mydriasis, cycloplegia and penalization of a healthy eye in the treatment of amblyopia;

Cyclogyl (cyclopentolate hydrochloride ophthalmic solution, USP), an anticholinergic used to produce mydriases and cycloplegia;

Mydriacyl (tropicamide ophthalmic solution, USP), an anticholinergic for mydriasis and cycloplegia for diagnostic procedures;

Cyclomydril (cyclopentolate hydrochloride and phenylephrine hydrochloride ophthalmic solution) for the production of mydriasis;

Fluorescite (fluorescein injection, USP, 10%) for diagnostic fluorescein angiography or angioscopy of the retina and iris vasculature; and

Tetracaine hydrochloride ophthalmic solution 0.5% Steri-Unit, an ester local anesthetic.

“At Alcon, we strive to provide surgeons the most complete line of ophthalmic products available — not only through innovations in technology, but now through a portfolio of mydriatic, cycloplegic, diagnostic and anesthetic products,” Brian O’Neal, Alcon’s head of marketing, US Surgical, said in the release. “With the transition of this portfolio from Novartis, we’re excited to provide our customers with a comprehensive line of products to support surgical and clinical ophthalmic procedures.”